Altre lingue Bionomics Limited

Azioni

BNOX

US09063M2052

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 17/05/2024			Variaz. 5gg	Var. 1 gen.
0,9024 ^USD	-2,22%		-5,12%	-39,03%

21/03	Bionomics riporta i risultati dell'analisi del set di dati completo dello studio ATTUNE di Fase 2b di BNC210 in pazienti con disturbo da stress post-traumatico	CI
15/03	Bionomics Limited riporta i risultati degli utili per il semestre conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	21/03
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	21/03
Bionomics : Notes to the Consolidated Financial Statements - Form 6-K	15/03
Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	15/03
Bionomics to Present at the 2024 BIO CEO & Investor Conference	22/02
Small-Cap Nasdaq Stocks to Watch Now! VTAK, BNOX, INBS, DYAI, KAVL	29/01
Wall Street Set to Open Higher in Monday Trading Ahead of Economic Indicators Data	22/01
US Futures Poised to Open Week Higher, Leading Economic Indicators on Tap	22/01
Bionomics Provides a Review of 2023 and of 2024 Plans	22/01
Bionomics to Present at Biotech Showcase™ 2024	05/01
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting	06/12
Bionomics : Results of Annual General Meeting - Form 6-K	30/11
Bionomics : • Operations Presentation	30/11
Bionomics : Announces Retirement of Board Member - Form 6-K	28/11
Bionomics Limited Announces Retirement of Dr. Errol De Souza as Board of Directors, Effective November 30, 2023	28/11
Bionomics : Announces Retirement of Board Member	28/11
ADRs End Higher, Yoshitsu Co. Ltd. Climbs 19.2%	10/11
Bionomics : Notice of Annual General Meeting Explanatory Statement and Proxy Form - Form 6-K	03/11
Bionomics to Advance Social Anxiety Disorder Treatment Into Phase 3 Studies After End-of-Phase 2 Meeting With US FDA	16/10/23
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder	16/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Bionomics Limited

Azioni

BNOX

US09063M2052

Altre lingue

Filtri